LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Beats Revenue Estimates

Core Insights - LENZ Therapeutics, Inc. reported a quarterly loss of $0.59 per share, which was better than the Zacks Consensus Estimate of a loss of $0.67, representing an earnings surprise of +11.94% [1] - The company generated revenues of $12.5 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 92.31%, compared to zero revenues a year ago [2] - LENZ Therapeutics shares have declined approximately 2.8% year-to-date, while the S&P 500 has increased by 15.1% [3] Earnings Outlook - The future performance of LENZ Therapeutics' stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - The current consensus EPS estimate for the upcoming quarter is -$0.92 on revenues of $3.46 million, and for the current fiscal year, it is -$2.62 on revenues of $14.27 million [7] Estimate Revisions - Prior to the earnings release, the estimate revisions trend for LENZ Therapeutics was favorable, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]